Clinical Trial Update: Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2a trial evaluating the efficacy, safety, and tolerability of GIA632 in adults with moderate-to-severe atopic dermatitis; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• GIA632

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Atopic Dermatitis | Phase 2 | Status: RECRUITING